UBS’s Neurogene NGNE Stock Holding History

UBS’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$20K	Buy	+147	New	+$22.4K	﹤0.01%	8022
2014 Q2	–	Sell	-46	Closed	-$12K	–	10680
2014 Q1	$12K	Buy	+46	New	+$11.8K	﹤0.01%	8693

Other funds holding NGNE

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

UBS's NGNE Position: Q3 2014 in Review

UBS opened a new position in Neurogene (NGNE) in Q3 2014: 147 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #8022 among its holdings. This is a return to the name: UBS previously reported a position in NGNE as recently as Q1 2014.

UBS first reported a position in NGNE in Q1 2014 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold NGNE as of Q3 2014.

UBS held 147 shares of Neurogene worth $20K as of Q3 2014.
Neurogene was a new UBS position in Q3 2014.
Neurogene made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8022 holding.
UBS first reported a position in Neurogene in Q1 2014 and has held it in 2 quarters since.
22 funds tracked by Wall St. Rank held Neurogene as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.